How well does your CLL medical affairs team performance compare with the rest?
Is ‘moderately satisfied’ good enough? According to this latest survey of 100 US medical oncologists and haematologists, the performance of chronic lymphocytic leukaemia medical affairs teams still has a way to go in some key areas before higher satisfaction ratings can be achieved across the board. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied.
Use Medical Affairs Reputations: Chronic Lymphocytic Leukaemia 2017 (US) to discover how your team can better meet the high expectations of physicians at the frontline.
This report compares the current activities of medical affairs teams for the six leading CLL treatments from Novartis, Gilead, Roche, Janssen Biotech, AbbVie and Biogen. It shows:
How physicians rate each team overall, and for 12 key medical affairs services.
What is most important to physicians, plus what can be done better.
How, and how often physicians want to meet with your team.
It’s time to find out exactly how well your medical affairs team is performing against fierce competition – and establish an action plan to gain competitive advantage
Interested in the European market? Click here to see the EU5 Edition.
Stand out or forgettable? One team strides ahead with 85% of physicians recalling an interaction within the last 6 months – whereas another is lagging way behind with a half-hearted response. How does your team stack up?
Patient focus: How much do US physicians rely on medical affairs to help them improve patient access, education and outcomes? And are they spending more or less time doing this than before?
Not so dynamic duo: Two teams top the satisfaction table for many (but not all) medical affairs attributes. Where are their weak spots and who is maximising on them?
Shared goal: Physicians identified the same important opportunity for improvement for 3 out of 6 medical affairs teams. Just what should all of them be focusing on right now?
Good news for all: Physicians praised every drug for at least 4 areas of support provided by medical affairs teams.
Consider the 80:20 rule: 1 in 5 survey respondents suggest more can be done to provide specific information, and that attitudes could be improved. Could addressing these tip the balance?
Insight into Medical Affairs Teams for These CLL Brands
Arzerra (ofatumumab; Novartis)
Gazyva (obinutuzumab; Roche)
Imbruvica (ibrutinib; Janssen Biotech/AbbVie)
Rituxan (rituximab; Roche/Biogen)
Venclexta (venetoclax; Roche/AbbVie)
Zydelig (idelalisib; Gilead)
An Expert-designed Competitive View of Your Medical Affairs Team
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 7 medical affairs teams—answering important questions like:
What do physicians need?
How, and how often are they using your medical affairs team?
What services do they consider most important?
How often should you contact them? What channels are best?
Does your medical affairs team deliver?
How memorable are your team’s interactions with doctors?
How do doctors rank your team for performance and satisfaction in 12 key areas?
How does your team compare to the competition—in each area, and overall?
What needs improvement?
Are you delivering the services that are most important to doctors?
Where do you need to improve?
How can your team enhance its services?
Based on Interviews with Practicing Doctors
We surveyed 100 US-based medical oncologists and haematologists—chosen from the largest community of validated physicians in the world.
Have been practicing for between 3 and 35 years
See at least 5 patients with CLL in a typical month
Devote at least 50% of their time to direct patient care
Have interacted with at least one listed product’s medical affairs team in the past 6 months.
We conducted the survey between August 1st and 16th, 2017.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success. FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.